Replimune Group (NASDAQ:REPL) Stock Price Up 3.8% After Analyst Upgrade

Replimune Group, Inc. (NASDAQ:REPL)’s stock price rose 3.8% during mid-day trading on Wednesday after JPMorgan Chase & Co. raised their price target on the stock from $14.00 to $17.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. Replimune Group traded as high as $11.50 and last traded at $11.49. Approximately 89,276 shares changed hands during trading, a decline of 92% from the average daily volume of 1,124,411 shares. The stock had previously closed at $11.07.

Other equities research analysts have also issued reports about the stock. Roth Capital raised shares of Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. Roth Mkm started coverage on shares of Replimune Group in a research note on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price objective for the company. Barclays upped their target price on shares of Replimune Group from $13.00 to $17.00 and gave the stock an “overweight” rating in a report on Friday, June 7th. HC Wainwright reissued a “buy” rating and set a $17.00 price target on shares of Replimune Group in a report on Monday, September 16th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $16.00 price objective on shares of Replimune Group in a research note on Thursday, June 6th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $16.80.

Insider Buying and Selling

In other Replimune Group news, CFO Emily Luisa Hill sold 8,938 shares of Replimune Group stock in a transaction on Friday, August 16th. The shares were sold at an average price of $10.18, for a total value of $90,988.84. Following the sale, the chief financial officer now directly owns 101,057 shares in the company, valued at approximately $1,028,760.26. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 20.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Nisa Investment Advisors LLC lifted its position in shares of Replimune Group by 10,304.2% during the second quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock worth $45,000 after purchasing an additional 4,946 shares during the last quarter. Point72 DIFC Ltd bought a new stake in Replimune Group during the 2nd quarter valued at about $57,000. Quest Partners LLC purchased a new stake in Replimune Group in the 4th quarter valued at about $76,000. Diversified Trust Co purchased a new stake in Replimune Group in the 1st quarter valued at about $94,000. Finally, China Universal Asset Management Co. Ltd. grew its stake in Replimune Group by 72.8% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 11,808 shares of the company’s stock worth $96,000 after acquiring an additional 4,975 shares in the last quarter. 92.53% of the stock is currently owned by institutional investors.

Replimune Group Stock Performance

The stock’s 50-day moving average price is $10.28 and its 200 day moving average price is $8.46. The company has a debt-to-equity ratio of 0.16, a quick ratio of 13.46 and a current ratio of 13.46.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.10. Sell-side analysts anticipate that Replimune Group, Inc. will post -3.11 earnings per share for the current year.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.